MedTrace Logo

Pharmacogenetics of Gastrointestinal Bleeding

NCT00190255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2011-05-10

No results posted yet for this study

Summary

Gastrointestinal bleeding is a severe adverse effect occurring in subjects secondary to the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The enzyme CYP2C9 is responsible for the elimination of several NSAIDs. This protein is inactive in 12% of the subjects because of genetic mutations. We hypothesized that individuals carrying such mutations should be at higher risk of gastrointestinal bleeding since they display decreased NSAIDs elimination.

Conditions

  • Gastrointestinal Hemorrhage
  • Stomach Ulcer
  • Non-steroidal Anti-inflammatory Drug Sensitivity

Interventions

PROCEDURE

CY2PC9 genotyping

CY2PC9 genotyping

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Nicolas CARBONNELL, MD · Assistance Publique - Hôpitaux de Paris

  • Laurent BECQUEMONT, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00190255 on ClinicalTrials.gov